Bailard, Inc. Aerie Pharmaceuticals Inc Transaction History

Bailard, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 26, 2019	SELL	$28.97 - $48.21 $188,305 - $313,365	-6,500 Closed	0 $0
Q2 2018 Aug 08, 2018	SELL	$47.85 - $70.45 $772,777 - $1.14 Million	-16,150 Reduced 71.3%	6,500 $439,000
Q4 2017 Feb 08, 2018	BUY	$50.85 - $65.1 $274,590 - $351,539	5,400 Added 31.3%	22,650 $0
Q3 2017 Oct 11, 2017	SELL	$48.6 - $60.1 $838,350 - $1.04 Million	-17,250 Reduced 50.0%	17,250 $838,000
Q2 2017 Aug 11, 2017	SELL	N/A	-16,000 Reduced 31.68%	34,500 $0
Q1 2017 Jan 29, 2018	SELL	N/A	-32,500 Reduced 39.16%	50,500 $2.29 Million
Q3 2016 Jan 29, 2018	SELL	N/A	-30,000 Reduced 26.55%	83,000 $3.13 Million
Q1 2016 Jan 29, 2018	BUY	N/A	93,000 Added 465.0%	113,000 $1.37 Million
Q4 2015 Jan 29, 2018	SELL	N/A	-13,000 Reduced 39.39%	20,000 $0
Q3 2015 Jan 29, 2018	BUY	N/A	33,000	33,000 $585,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.